Find Ensifentrine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Rpl-554, 298680-25-8, Rpl554, 1884461-72-6, Ensifentrine [inn], Ensifentrine [usan]
Molecular Formula
C26H31N5O4
Molecular Weight
477.6  g/mol
InChI Key
CSOBIBXVIYAXFM-UHFFFAOYSA-N
FDA UNII
3E3D8T1GIX

Ensifentrine
Ensifentrine is an inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), with potential anti-inflammatory and bronchodilator activities. Upon administration, ensifentrine targets, binds to and inhibits PDE3 and PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling. This may lead to bronchial smooth muscle relaxation and modulate inflammatory responses. PDE3 and PDE4, members of the PDE superfamily, hydrolyze cAMP and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5' monophosphates. PDE3 is the most expressed PDE isoenzyme in bronchial smooth muscle. PDE4 is expressed in immune cells including T-cells, monocytes, macrophages, neutrophils, dendritic cells and eosinophils. It plays an important role in inflammation, especially in inflammatory airway diseases.
1 2D Structure

Ensifentrine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-3-yl]ethylurea
2.1.2 InChI
InChI=1S/C26H31N5O4/c1-15-10-16(2)24(17(3)11-15)29-23-14-20-19-13-22(35-5)21(34-4)12-18(19)6-8-30(20)26(33)31(23)9-7-28-25(27)32/h10-14H,6-9H2,1-5H3,(H3,27,28,32)
2.1.3 InChI Key
CSOBIBXVIYAXFM-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2CCNC(=O)N)OC)OC)C
2.2 Other Identifiers
2.2.1 UNII
3E3D8T1GIX
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimidino(6,1-a)isoquinolin-4-one

2. Rpl 554

3. Rpl-554

4. Rpl554

2.3.2 Depositor-Supplied Synonyms

1. Rpl-554

2. 298680-25-8

3. Rpl554

4. 1884461-72-6

5. Ensifentrine [inn]

6. Ensifentrine [usan]

7. Ls-193855

8. 3e3d8t1gix

9. Ls-193,855

10. A]isoquinolin-3(4h)-yl}ethyl)urea

11. (e)-1-(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2h-pyrimido[6,1-a]isoquinolin-3(4h)-yl)ethyl)urea

12. 2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-3-yl]ethylurea

13. Trimethylphenyl)imino]-6,7-dihydro-2h-pyrimido[6,1-

14. N-(2-{(2e)-9,10-dimethoxy-4-oxo-2-[(2,4,6-

15. 2-(9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido(6,1-a)isoquinolin-3-yl)ethylurea

16. N-(2-((2e)-9,10-dimetoxi-4-oxo-2-((2,4,6-trimetilfenil)imino)-6,7-dihidro-2h-pirimido(6,1-a)isoquinolein-3(4h)-il)etil)urea

17. Urea, N-(2-(6,7-dihydro-9,10-dimethoxy-4-oxo-2-((2,4,6-trimethylphenyl)imino)-2h-pyrimido(6,1-a)isoquinolin-3(4h)-yl)ethyl)-

18. Unii-3e3d8t1gix

19. Vmx-554

20. Rpl-554;ensifentrinum

21. Ensifentrine (usan/inn)

22. Ensifentrine [who-dd]

23. Schembl625876

24. Chembl4594287

25. Schembl20720900

26. Gtpl11865

27. Dtxsid00183983

28. Bcp31840

29. Ex-a6633

30. Who 10726

31. Sb19810

32. D11743

33. A937318

34. Q7277486

35. Ensifentrina; Ensifentrinum;rpl-554;rpl554;rpl 554

36. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimidino(6,1-a)isoquinolin-4-one

37. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one

38. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one

39. 9,10-dimethoxy-2-(2.4.6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6.1-a]isoquinolin-4-one

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 477.6 g/mol
Molecular Formula C26H31N5O4
XLogP32.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass477.23760449 g/mol
Monoisotopic Mass477.23760449 g/mol
Topological Polar Surface Area110 Ų
Heavy Atom Count35
Formal Charge0
Complexity849
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

NDC API

read-more
read-more

01

Boulder Peptide 2024
Not Confirmed
arrow
arrow
Boulder Peptide 2024
Not Confirmed

ENSIFENTRINE

NDC Package Code : 50909-1705

Start Marketing Date : 2023-04-12

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNeuland Laboratories- A dedicated 100% API provider.

Flag India
Digital Content Digital Content

Ensifentrine

About the Company : Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the p...

Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. Neuland’s expertise is in the manufacturing of APIs and advanced intermediates from its USFDA-approved facilities. Its core competency lies in the application of powerful process chemistry to manufacturing in a regulatory-compliant environment.
Neuland

02

Seqens

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Flag France
Digital Content Digital Content

Ensifentrine

About the Company : Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling ...

Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling up and manufacturing drug substances from the pre-clinical phase to the commercial phase. It offers a large portfolio of APIs and proprietary products. Seqens also develops custom solutions and ingredients for the most demanding industries, such as healthcare, electronics and cosmetics. Its unique range of technologies enables it to manufacture complex molecules for small- and large-scale demands. It operates 24 industrial plants and 10 R&D centres across the globe.
Seqens Company Banner

03

Angene International

United Kingdom
Boulder Peptide 2024
Not Confirmed
arrow

Angene International

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Ensifentrine

About the Company : Angene is pledged to providing quality chemicals for use in research and development and commercial manufacturing. Angenes offers over 100,000 products including lab reagents, inte...

Angene is pledged to providing quality chemicals for use in research and development and commercial manufacturing. Angenes offers over 100,000 products including lab reagents, intermediates, bulk commodities, agro-chemicals, natural ingredients and active pharmaceutical ingredients (APIs). In addition to the 100,000+ products, Angene offers custom synthesis of chemicals that are not commercially available.
blank

04

Chemicea

India
Boulder Peptide 2024
Not Confirmed
arrow

Chemicea

India
arrow
Boulder Peptide 2024
Not Confirmed

Ensifentrine

About the Company : Chemicea Pharmaceuticals is a reputable contract research organization based in Pune, India. Specializing in chemistry-driven solutions, Chemicea offers a wide range of R&D product...

Chemicea Pharmaceuticals is a reputable contract research organization based in Pune, India. Specializing in chemistry-driven solutions, Chemicea offers a wide range of R&D products and services tailored for Pharmaceutical/Biotech companies and research institutes. Certified under ISO 9001:2015, the company excels in providing pharmaceutical impurities such as Process Impurities, Degradation Impurities, API Intermediates, and Custom Synthesis. Their expertise lies in delivering high-quality solutions crucial for the development and production processes within the pharmaceutical industry.
blank

05

Boulder Peptide 2024
Not Confirmed
arrow
arrow
Boulder Peptide 2024
Not Confirmed

Ensifentrine

About the Company : Glixx Laboratories Inc (Glixx) is a global leading company specializing in biological research chemicals, providing services to meet the needs of biomedical research markets. With ...

Glixx Laboratories Inc (Glixx) is a global leading company specializing in biological research chemicals, providing services to meet the needs of biomedical research markets. With its fast and efficient synthesis, the Glixx R&D team focuses on commercializing newly discovered research chemicals and bringing them to the life sciences R&D communities. Our company goal is to help our community by lowering the cost of the essential chemicals for research needs, to better progress on to new discoveries in drug development, medical screening, and all facets of scientific innovations.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Ohtuvayre (ensifentrine), is a first-in-class PDE3/4 inhibitor product candidate, which is being evaluated for the maintenance treatment of chronic obstructive pulmonary disease.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ohtuvayre

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2024

blank

01

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Details : Ohtuvayre (ensifentrine), is a first-in-class PDE3/4 inhibitor product candidate, which is being evaluated for the maintenance treatment of chronic obstructive pulmonary disease.

Brand Name : Ohtuvayre

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 26, 2024

blank

Details:

The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of chronic obstructive pulmonary disease.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Oaktree Capital Management, L.P

Deal Size: $650.0 million Upfront Cash: Undisclosed

Deal Type: Financing May 09, 2024

blank

02

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Details : The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of ...

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Undisclosed

May 09, 2024

blank

Details:

The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of chronic obstructive pulmonary disease.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Oxford Finance

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing January 02, 2024

blank

03

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Details : The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of ...

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Undisclosed

January 02, 2024

blank

Details:

RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 11, 2023

blank

04

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-infla...

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 11, 2023

blank

Details:

RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 27, 2023

blank

05

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-infla...

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 27, 2023

blank

Details:

RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 10, 2023

blank

06

Boulder Peptide 2024
Not Confirmed
Boulder Peptide 2024
Not Confirmed

Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-infla...

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 10, 2023

blank

Details:

Ensifentrine is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2023

blank

07

Boulder Peptide 2024
Not Confirmed
Boulder Peptide 2024
Not Confirmed

Details : Ensifentrine is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory b...

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 06, 2023

blank

Details:

Ensifentrine (RPL554) is an investigational, first-in-class, selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 that combines bronchodilator and anti-inflammatory activities in one compound.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 20, 2022

blank

08

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Details : Ensifentrine (RPL554) is an investigational, first-in-class, selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 that combines bronchodilator and anti-inflammatory activities in one compound.

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 20, 2022

blank

Details:

RPL554 (ensifentrine), met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in the ENHANCE-2 trial.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 19, 2022

blank

09

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Details : RPL554 (ensifentrine), met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function. In addition, ensifentrine significantly reduced the...

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 19, 2022

blank

Details:

The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine (RPL554), the first-in-class product candidate, which reported positive Phase 3 data in the ENHANCE-2 trial in chronic obstructive pulmonary disease.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Oxford Finance LLC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing October 17, 2022

blank

10

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Details : The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine (RPL554), the first-in-class product candidate, which reported positive Phase 3 data...

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Undisclosed

October 17, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

VERONA PHARMA

United Kingdom
Boulder Peptide 2024
Not Confirmed
arrow

VERONA PHARMA

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

ENSIFENTRINE

Brand Name : OHTUVAYRE

Dosage Form : SUSPENSION;INHALATION

Dosage Strength : 3MG/2.5ML

Approval Date : 2024-06-26

Application Number : 217389

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

Verona Pharma

United Kingdom
Boulder Peptide 2024
Not Confirmed
arrow

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Ensifentrine

Brand Name : Ohtuvayre

Dosage Form :

Dosage Strength :

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : United Kingdom

blank

01

Verona Pharma

United Kingdom
Boulder Peptide 2024
Not Confirmed
arrow

Verona Pharma

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

Ensifentrine

Dosage :

Dosage Strength :

Brand Name : Ohtuvayre

Approval Date :

Application Number :

Registration Country : United Kingdom

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
FDA approvals slump 19% in H1 2024; NASH, COPD, PAH get new treatment options
The first half of 2024 saw a significant slowdown in approvals of new drugs and biologics by the US Food and Drug Administration (FDA) compared to the same period last year.FDA’s Center for Drug Evaluation and Research (CDER) approved 21 drugs in H1 2024, reflecting a 19 percent decrease from the 26 approvals granted in H1 2023.  Of them, 81 percent (17) were first-in-class drugs (therapies that use a new and unique mechanism of action), while small molecules made up for 67 percent (14) of the total drugs approved.Similarly, the Center for Biologics Evaluation and Research (CBER) granted approvals to only eight biologics, as compared to 10 in H1 2023.Health Canada also saw a drop in drug approvals as only 10 drugs were okayed in H1 2024, as opposed to 13 approvals in H1 2023.The European Medicines Agency (EMA) saw a marginal rise in drug authorizations at 15 for H1 2024 as compared to 14 approvals in H1 2023. Interestingly, the EMA also saw a surge in pending decisions (applications under review) — from two in H1 2023 to 14 in H1 2024.View New Drug Approvals in H1 2024 with Estimated Sales (Free Excel Available)Merck, Madrigal, Verona bag approvals for breakthrough meds; Lilly’s donanemab okayedThe first half saw some closely watched drugs win regulatory approvals. FDA approved a breakthrough therapy from Merck — Winrevair (sotatercept) — that treats adults with hypertension caused by the constriction of arteries in the lungs, known as pulmonary arterial hypertension (PAH).Merck had acquired Winrevair through its US$ 11.5 billion acquisition of Acceleron Pharma in 2021. The therapy is set to generate nearly US$ 3 billion in global peak sales by 2028. Another breakthrough therapy approved in H1 2024 is Madrigal’s Rezdiffra (resmetirom), the first FDA-approved treatment for adults with the common fatty liver disease — nonalcoholic steatohepatitis (NASH). Rezdiffra is expected to touch sales of US$ 2.1 billion by 2028.The agency also approved the first maintenance treatment for chronic obstructive pulmonary disease (COPD) in over 20 years — Verona’s Ohtuvayre. The drug has a novel mechanism of action and is the first inhaled maintenance treatment for COPD. Approved in June by the FDA, Ohtuvayre is forecast to bring in global sales of US$ 1.5 billion by 2030.The approval of Eli Lilly’s donanemab was surprisingly delayed, and finally came through on July 2 after an FDA advisory committee voted unanimously in favor of its benefits outweighing its risks. To be sold as  Kinsula, the Alzheimer's drug is estimated to bring in US$ 2.2 billion in sales by 2028.Across the pond, EMA approved Novo Nordisk’s weekly insulin injection Awiqli (insulin icodec). The replacement insulin in Awiqli acts in the same way as the body’s own insulin and helps glucose enter cells from the blood. Meanwhile, FDA rejected this once-a-week insulin earlier this month and has requested information related to the manufacturing process.View New Drug Approvals in H1 2024 with Estimated Sales (Free Excel Available) ImmunityBio, Geron, Day One win approvals for their oncology drugsIn what marks the first approval for ImmunityBio, FDA greenlit Anktiva (nogapendekin alfa inbakicept-pmln) as part of a combination therapy to treat a type of bladder cancer. Anktiva is a next-generation immunotherapy that creates long-term immunity by activating the so-called natural killer (NK) cells and T-cells. It will compete with Merck’s Keytruda. Anktiva’s yearly sales by 2030 are expected to be around US$ 1.7 billion.BeiGene’s PD-1 blocker Tevimbra (tislelizumab) got the go-ahead from the FDA as the treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. Tevimbra’s 2028 global sales are forecast to bring in US$ 1.6 billion.FDA signed off on Geron’s Rytelo (imetelstat) for treating transfusion-dependent anemia in patients with low- to intermediate-risk myelodysplastic syndromes (MDS), a group of blood cancers. This was Geron’s maiden approval and Rytelo is expected to bring in US$ 1.3 billion by 2030.Day One Biopharmaceuticals’ Ojemda (tovorafenib) was granted FDA’s accelerated approval to treat certain types of pediatric brain cancer. This is the first FDA approval of a systemic therapy for treating what is the most common form of childhood brain tumor, including fusions. Ojemda is forecast to bring in US$ 1 billion in sales by 2030.FDA granted accelerated approval to Amgen’s Imdelltra (tarlatamab-dlle) for adults in advanced stages of small cell lung cancer (SCLC) that has proven to be hard to treat or has worsened despite platinum-based chemotherapy. Imdelltra is expected to bring in annual sales of US$ 975 million by 2030.View New Drug Approvals in H1 2024 with Estimated Sales (Free Excel Available) Infectious disease drugs from Basilea, Merck, rare disease med from Ipsen bag  approvalsAfter oncology, infections and infectious diseases, and rare diseases were the two therapeutic areas that saw the second and third most approvals, respectively. FDA approved Basilea Pharmaceutica’s Zevtera (ceftobiprole medocaril sodium for injection), an antibiotic for bacterial infections including multidrug-resistant strains.The US agency also approved Merck’s next-generation vaccine designed to protect adults from pneumococcus bacteria that causes serious illnesses and pneumonia. The jab, known as Capvaxive, helped produce an immune response against all 21 variations (serotypes) of the bacteria that it targeted. These 21 strains account for about 85 percent of invasive pneumococcal disease cases in adults aged 65 and above. FDA also approved Moderna’s mRESVIA, a messenger RNA-based (mRNA) respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by the syncytial virus. This is the first non-Covid mRNA vaccine to be approved in the US.The agency granted accelerated approval to Ipsen’s Iqirvo (elafibranor) to treat primary biliary cholangitis (PBC), a rare liver disease. This is the first new medicine approved in nearly a decade for the treatment of PBC. Orchard Therapeutics’ Lenmeldy secured FDA approval to become the first gene therapy in the US for a rare pediatric disorder, known as metachromatic leukodystrophy (MLD). The debilitating hereditary disease affects the brain and the nervous system and causes loss of cognitive and motor functions and early death.View New Drug Approvals in H1 2024 with Estimated Sales (Free Excel Available) Our viewThe increased momentum of drug approvals witnessed after the pandemic appears to have slowed down, but what’s encouraging is the increase in first-in-class therapies, cancer drugs and promising new treatment options for a range of conditions such as PAH, NASH, and COPD.The second half has already kicked off with the approval of Lilly’s donanemab. And there are several pathbreaking drugs likely to be approved soon, such as Karuna Therapeutics’ schizophrenia drug KarXT and BridgeBio’s heart drug acoramidis. There is every possibility that new drug approvals will spring back up in H2 2024. 

Impressions: 1668

https://www.pharmacompass.com/radio-compass-blog/fda-approvals-slump-19-in-h1-2024-nash-copd-pah-get-new-treatment-options

#PharmaFlow by PHARMACOMPASS
25 Jul 2024

STOCK RECAP #PipelineProspector

read-more
read-more
Pipeline Prospector June 2024: FDA approves Merck’s next-gen pneumococcal vaccine, Verona’s COPD therapy
The pharma indices were back in the black in May, and the good streak continued through June with the Nasdaq Biotechnology Index (NBI) gaining 3 percent, the SPDR S&P Biotech ETF (XBI) index up over 3.1 percent and the S&P Biotechnology Select Industry Index (SPSIBI) rising 4.25 percent.The two summer months were similar in more ways than one. In May, Eli Lilly had announced an investment of US$ 5.3 billion to boost the supply of Zepbound and Mounjaro. In June, Novo Nordisk followed suit, investing US$ 4.1 billion to develop a new manufacturing facility to boost the supply of Ozempic and Wegovy.Similarly, the US Food and Drug Administration (FDA) continued to grant vaccine approvals in June after okaying Moderna’s mRNA respiratory syncytial virus (RSV) vaccine in May. Last month, Merck’s next-generation pneumococcal vaccine won an FDA nod, and the agency expanded the use of GSK’s respiratory syncytial virus (RSV) vaccine to include adults aged 50 to 59.However, June was a lackluster month for mergers and acquisitions. The month had to be content with some tie-ups. For instance, Roche signed an up to US$ 1.8 billion deal with Boston-based startup Ascidian Therapeutics to discover and develop novel gene therapies for difficult-to-treat neurological diseases. AbbVie inked a US$ 1.7 billion agreement with China’s FutureGen to bring the latter’s next-generation treatment (FG-M701) for inflammatory bowel disease to market. Takeda signed an option agreement with China’s Ascentage Pharma for an exclusive license to a promising drug for chronic myeloid leukemia and other blood cancers. And Day One Biopharmaceuticals struck a licensing deal with MabCare for a novel antibody drug conjugate (ADC) to treat multiple cancers. The deal’s potential value is US$ 1.2 billion.Access the Pipeline Prospector Dashboard for June 2024 Newsmakers (Free Excel)Merck’s pneumococcal jab wins FDA nod; Moderna’s combo vaccine scores trial winVaccines took centerstage in June. FDA approved Merck’s Capvaxive, a next-generation pneumococcal vaccine designed to protect adults from a broader range of pneumococcus bacteria strains that cause serious illnesses and pneumonia. Capvaxive targets 21 bacterial variations responsible for about 85 percent of invasive pneumococcal disease cases in older adults. Similarly, GSK secured FDA approval for its RSV vaccine for adults aged 50 to 59 years. This makes Arexvy the only RSV shot endorsed for that age group.In a late-stage trial, Moderna’s mRNA-1083, an investigational combination vaccine against influenza and Covid, elicited a higher immune response compared to separate shots in people aged 50 and over. The combo jab generated more antibodies than currently marketed flu vaccines and Moderna’s Spikevax. And the world’s first personalized mRNA cancer vaccine from Moderna has raised hopes for patients with skin cancer, as three-year data from a mid-stage trial showed some benefits on patients who took the vaccine in combination with Merck’s Keytruda.Despite these developments, Moderna’s stock dropped 19 percent in June after it said the efficacy of its RSV vaccine mRESVIA had vaned substantially to 50 percent after 18 months.Access the Pipeline Prospector Dashboard for June 2024 Newsmakers (Free Excel) Verona, Geron score maiden FDA approvals; BMS’ Augtyro bags tumor-agnostic nodTwo companies obtained their first FDA approvals last month. The first one was Verona Pharma (stock up 15 percent) — it received its maiden FDA approval for Ohtuvayre for treating chronic obstructive pulmonary disease (COPD). This is also the first inhaled COPD treatment with a novel mechanism of action.The second company to get its maiden FDA approval was Geron, a commercial-stage biopharmaceutical company. FDA signed off on Geron’s Rytelo for treating transfusion-dependent anemia in patients with low- to intermediate-risk myelodysplastic syndromes (MDS), a group of blood cancers.In June, FDA granted accelerated approvals to at least three drugs. BMS’ Augtyro was granted FDA’s accelerated approval for treating adult and pediatric patients (over 12 years) with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, regardless of where they occur in the body.Ipsen received FDA’s accelerated approval for Iqirvo, a first-in-class, once-daily oral medication for treating primary biliary cholangitis (PBC), a progressive liver disease affecting mostly women.Sarepta Therapeutics’ (stock up 24 percent) Elevidys received accelerated approval for Duchenne muscular dystrophy (DMD) despite failing its primary endpoint in a late-stage trial.Amongst other approvals, Argenx’s Vyvgart Hytrulo was approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP). This is a novel treatment option for this rare and debilitating neuromuscular disorder. And BMS’ Krazati got its second approval for treating colorectal cancer with a specific KRAS mutation.Access the Pipeline Prospector Dashboard for June 2024 Newsmakers (Free Excel) GSK’s failed cancer drug posts trial win; Gilead’s HIV prophylaxis shows efficacyIn late-stage trials, GSK’s multiple myeloma therapy Blenrep cut the risk of disease progression or death by almost half compared to standard-of-care treatments. The once-failed ADC was pulled from the lucrative US market in 2022, but the results could signal a comeback for Blenrep.Intra-Cellular’s antipsychotic drug Caplyta scored another remarkable late-stage win for treating major depressive disorder (MDD). In another late-stage trial, Gilead’s (stock up 6 percent) long-acting injection proved to be more effective in preventing HIV infection in women compared to the daily pill Truvada. This is the first time that an HIV pre-exposure prophylaxis (PrEP) has shown zero infections in a phase 3 trial, the drugmaker said. Dosed just twice a year, Sunlenca could be a game-changer in HIV prevention. Analysts estimate that PrEP-related sales could be over US$ 1.7 billion.In a blow to millions affected by long Covid, Pfizer’s Paxlovid did not appear to improve the symptoms as was hoped. Pfizer’s stock fell 7 percent in June.Access the Pipeline Prospector Dashboard for June 2024 Newsmakers (Free Excel) Our view This was the second month when pharma indices showed an upward trend. It’s been a good first half for the US stock markets. But there are mixed reports on how markets will perform in the second half, given the uncertainties around interest rate cuts and the outcome of the presidential elections in the US slated to be held in November. Though for those tracking biopharma news, there are enough interesting developments to fret over the markets.Access the Pipeline Prospector Dashboard for June 2024 Newsmakers (Free Excel) 

Impressions: 2453

https://www.pharmacompass.com/pipeline-prospector-blog/pipeline-prospector-june-2024-fda-approves-merck-s-next-gen-pneumococcal-vaccine-verona-s-copd-therapy

#PharmaFlow by PHARMACOMPASS
04 Jul 2024

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/ritedose-is-proud-to-partner-with-verona-pharma-to-deliver-first-in-class-copd-drug-ohtuvayre-ensifentrine-302250313.html

PR NEWSWIRE
17 Sep 2024

https://www.globenewswire.com/news-release/2024/08/08/2926587/0/en/Verona-Pharma-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
08 Aug 2024

https://www.globenewswire.com/news-release/2024/07/25/2918519/0/en/Verona-Pharma-to-Report-Second-Quarter-2024-Financial-Results-and-Provide-Corporate-Update.html

GLOBENEWSWIRE
24 Jul 2024

https://www.fiercepharma.com/pharma/icer-says-veronas-price-copd-treatment-ohtuvayre-will-restrict-access

FIERCE PHARMA
16 Jul 2024

https://www.globenewswire.com/news-release/2024/06/26/2904839/0/en/Verona-Pharma-Announces-US-FDA-Approval-of-Ohtuvayre-ensifentrine.html

GLOBENEWSWIRE
26 Jun 2024

https://www.fiercepharma.com/pharma/veronas-ensifentrine-will-be-paradigm-shift-copd-treatment-globaldata-says

FIERCE PHARMA
30 May 2024

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Boulder Peptide 2024
Not Confirmed

VERONA PHARMA

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

ENSIFENTRINE

US Patent Number : 10945950

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 217389

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-15

blank

02

arrow
Boulder Peptide 2024
Not Confirmed

VERONA PHARMA

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

ENSIFENTRINE

US Patent Number : 9062047

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 217389

Patent Use Code : U-3962

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-08-21

blank

03

arrow
Boulder Peptide 2024
Not Confirmed

VERONA PHARMA

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

ENSIFENTRINE

US Patent Number : 9956171

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 217389

Patent Use Code : U-3962

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-15

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
Boulder Peptide 2024
Not Confirmed

VERONA PHARMA

United Kingdom
arrow
Boulder Peptide 2024
Not Confirmed

ENSIFENTRINE

Exclusivity Code : NCE

Exclusivity Expiration Date : 2029-06-26

Application Number : 217389

Product Number : 1

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty